Email this article Glucocorticoid induced osteoporosis in neurological patients: prevention and treatment
- Authors: Antonova K.V.1, Suponeva N.A.1, Shcherbakova N.I.1, Grishina D.A.1, Belova N.V.1, Kononova L.V.1
-
Affiliations:
- Research Center of Neurology
- Issue: Vol 7, No 2 (2017)
- Pages: 10-20
- Section: LECTURES AND REVIEWS
- Published: 28.09.2017
- URL: https://nmb.abvpress.ru/jour/article/view/203
- DOI: https://doi.org/10.17650/2222-8721-2017-7-2-10-20
- ID: 203
Cite item
Full Text
Abstract
Glucocorticoids (GCs) are often prescribed for neurologic patients. Autoimmune diseases of central and peripheral nervous system, neuromuscular disorders are associated with disability and life-threatening complications, and require long-term high-dosage administration of GCs. GC-therapy is a crucial decision to be made by a neurologist in collaboration with a patient, and requires strict observance of clear guidelines on the prevention, diagnosis and treatment of possible complications. One of the most frequent complications of GCs is osteoporosis. According to the Russian and international guidelines, all the patients must undergo preliminary and follow-up laboratory and instrumental examination, as well as administration of calcium and vitamin D during the whole period of GC-therapy. In case of a high fracture risk or if osteoporosis is diagnosed, antiresorptive therapy is indicated.
About the authors
K. V. Antonova
Research Center of Neurology
Email: belovanv22@yandex.ru
Russian Federation
N. A. Suponeva
Research Center of Neurology
Email: belovanv22@yandex.ru
Russian Federation
N. I. Shcherbakova
Research Center of Neurology
Email: belovanv22@yandex.ru
Russian Federation
D. A. Grishina
Research Center of Neurology
Email: belovanv22@yandex.ru
Russian Federation
N. V. Belova
Research Center of Neurology
Author for correspondence.
Email: belovanv22@yandex.ru
Russian Federation
L. V. Kononova
Research Center of Neurology
Email: belovanv22@yandex.ru
Russian Federation
References
Supplementary files
